Prognosis
Drug Giants Look for Growth Fuel as Older Blockbusters Show Age
- Cornerstone cancer drugs at Merck, Pfizer see gains level off
- As hit cancer franchises mature, hunt is on for new standouts
This article is for subscribers only.
The U.S.’s biggest pharmaceutical companies are beginning to prepare for a new and potentially challenging chapter after reaping the rewards of a fruitful period of cancer research that created new blockbusters.
First-quarter earnings reports on Tuesday from three drug giants showed that sales growth for some of the biggest-selling medicines of recent years is beginning to mature and slow -- and that companies are on the hunt for new therapies to keep their growth engines roaring.